Navigation Links
HIKMA - 2008 Preliminary Results Interview With CEO
Date:3/17/2009

LONDON, March 17 /PRNewswire-FirstCall/ -- Hikma Pharmaceuticals today announced strong revenue growth and stable net profits despite a loss at the company's US Generics business. The weakness in the US was offset by a strong performance from the multinational Pharma company's Injectable and Branded businesses. CEO, Said Darwazah, said "The US operations, in 2007, reported operating profit of about $30m and in 2008 we had a loss there so in spite of this $30m plus loss the other divisions, the Branded and the Injectables, performed so well, grew so much that they were able to offset that."

Noting the current macro economic downturn Mr Darwazah said Hikma's diversified business model, both by geography and product, would support growth in 2009. "It's going to be a very, very tough year. And the way we're going to address this, as we said, is by controlled growth. Growth of 10% to 15%."

It's free to view. All you need to do is register at http://www.cantos.com. Cantos.com, the online financial broadcaster, features in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email enquiries@cantos.com or phone +44-207-936-1333.


'/>"/>
SOURCE HIKMA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Hikma - 2007 Preliminary Results Interviews With CEO and CFO
2. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
3. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
4. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
5. CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million
6. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
7. Aidas Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer
8. Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial
9. Symmetry Medical Reports Preliminary Third Quarter Revenue
10. KV Pharmaceutical Company Reports Record Revenues for Fiscal 2008 Second Quarter and Six Months on a Preliminary Basis
11. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... England , January 23, 2017 ... today announces completion of its Series D financing, raising $35 ... one new investor, Wondfo Biotech. ... Development of the Atlas Genetics io® ... the Chlamydia trachomatis (CT) test announced in February 2016.  This ...
(Date:1/21/2017)... ... January 20, 2017 , ... G&L ... the healthcare industry ( http://www.gandlscientific.com ), has announced the opening of new offices ... and scientific consultants and contractors. This is the latest step in G&L’s expansion ...
(Date:1/21/2017)... , Jan. 20, 2017 Aratana Therapeutics, ... company focused on the licensing, development and commercialization of ... Pharm,s Best Company in North America ... the award based on the FDA approval ... (grapiprant tablets), ENTYCE ® (capromorelin oral solution) and ...
(Date:1/20/2017)... January 20, 2017 http://www.Financialbuzz.com ... one of leading causes of death worldwide. There were ... number of cancer related deaths increased gradually over time, ... incidence rate of various cancers continues to drive demand ... report by Global Market Insights, Inc. cancer biological therapy ...
Breaking Biology Technology:
(Date:12/15/2016)... 2016  There is much more to innovative access ... engine. Continental will demonstrate the intelligence of today,s solutions ... . Through the combination of the keyless entry and ... elements, the international technology company is opening up new ... "The integration of biometric elements brings our ...
(Date:12/12/2016)...  Researchers at Trinity College, Dublin, are opening ... the material with Silly Putty. The mixture (known as ... to sense pulse, blood pressure, respiration, and even ... The research team,s findings were published Thursday ... http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/8/2016)... Calif. , Dec. 8, 2016  Singulex, Inc., ... Molecule Counting technology, entered into a license and supply ... serving science. The agreement provides Singulex access to Thermo ... Europe is used to diagnose systemic ... United States to aid in assessing the ...
Breaking Biology News(10 mins):